Almost 40 Years of Tissue Engineering in Russia: Where Are We Now?

被引:0
|
作者
Alpeeva, Elena [1 ]
Sukhanov, Yury [1 ]
Vorotelyak, Ekaterina [1 ]
机构
[1] Russian Acad Sci, Dept Cell Biol, NK Koltzov Inst Dev Biol, Vavilov Str 26, Moscow 119334, Russia
关键词
regenerative medicine; tissue engineering; skin equivalent; wound healing; clinical trials; marketing authorization; legislation; state strategy of development; REGENERATION; EPITHELIUM;
D O I
10.3390/biomedicines8020025
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
This review describes achievements of Russian cell-based regenerative medicine in different periods of time depending on the legislation and politics, and future prospects for its commercialization and wide application with an emphasis on products devised for skin regeneration. The world's experience in tissue engineering began with the development of living skin equivalents, utilizing a biopolymer matrix and cells at the very beginning of the 1980s. During this period, the USSR kept abreast with the times and also conducted studies on skin wound healing, implementing modern cell techniques. However, there soon emerged a gap between scientific advancement and practical application. After the breakup of the USSR, there were no institutions that could implement scientific inventions into full-scale manufacturing for clinical application. At the same time, accumulating scientific and practical experience allowed for the maintenance of biomedical research and its readiness for market entry at present. Recently developed legislation opens up new opportunities in this field in Russia. There are a growing number of studies on the development of novel products for regenerative medicine, bringing hope for its rapid progress.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Vaccines against Tuberculosis: Where Are We Now?
    Srivastava, Shruti
    Dey, Sajal
    Mukhopadhyay, Sangita
    VACCINES, 2023, 11 (05)
  • [22] Progress in pain medicine: where are we now?
    Colvin, Lesley A.
    Rice, Andrew S. C.
    BRITISH JOURNAL OF ANAESTHESIA, 2019, 123 (02) : E173 - E176
  • [23] Retinal Organoid Technology: Where Are We Now?
    Zhang, Zuming
    Xu, Zihui
    Yuan, Fa
    Jin, Kangxin
    Xiang, Mengqing
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (19)
  • [24] Stem Cell Update: Where Are We Now?
    Bates, Mary
    IEEE PULSE, 2021, 12 (05) : 11 - 14
  • [25] Portable and wearable dialysis: where are we now?
    Davenport, Andrew
    Ronco, Claudio
    Gura, Victor
    HEMODIALYSIS INTERNATIONAL, 2010, 14 : S22 - S26
  • [26] Metformin and Breast Cancer: Where Are We Now?
    Cejuela, Monica
    Martin-Castillo, Begona
    Menendez, Javier A.
    Pernas, Sonia
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (05)
  • [27] Tissue engineering of the urethra: where are we in 2019? (vol 38, pg 2101, 2020)
    Chapple, Christopher
    WORLD JOURNAL OF UROLOGY, 2020, 38 (09) : 2107 - 2107
  • [28] Personalized treatment of neuropathic pain: Where are we now?
    Bouhassira, Didier
    Attal, Nadine
    EUROPEAN JOURNAL OF PAIN, 2023, 27 (09) : 1084 - 1098
  • [29] Stem cell therapy in stroke: Where are we now?
    Nih, Lina R.
    Levy, Bernard
    Kubis, Nathalie
    SANG THROMBOSE VAISSEAUX, 2012, 24 (03): : 119 - 124
  • [30] Fluorescent Probes for Imaging in Humans: Where Are We Now?
    Seah, Deborah
    Cheng, Zhiming
    Vendrell, Marc
    ACS NANO, 2023, 17 (20) : 19478 - 19490